Clinical experience with a controlled-release, prostaglandin E2 intravaginal insert in the USA.
Rayburn
W F
WF
Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City 73190, USA.
D000282:Administration, Intravaginal; D002626:Chemistry, Pharmaceutical; D018849:Controlled Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003692:Delayed-Action Preparations; D015232:Dinoprostone / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D005260:Female; D006801:Humans; D007751:Labor, Induced / Q000191:economics / Q000379:methods*; D010120:Oxytocics / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic
D003692:Delayed-Action Preparations; D010120:Oxytocics; D015232:Dinoprostone